Literature DB >> 12794820

Predicting mortality in patients with rheumatoid arthritis.

Frederick Wolfe1, Kaleb Michaud, Olaf Gefeller, Hyon K Choi.   

Abstract

OBJECTIVE: A number of different variables have been proposed as risk factors for mortality in patients with rheumatoid arthritis (RA), but limited prospective information on the magnitude of their effects is available. This study was undertaken to evaluate the relative predictive strength and usefulness of a wide range of variables on the risk of mortality in a large, long-term, prospectively studied cohort of patients with RA.
METHODS: Over a 20-year period of followup beginning in 1981, 1387 consecutive RA patients were seen in a single clinic. A wide range of clinical and demographic assessments were recorded and entered into a computer database at the time of each clinical assessment. Assessment of predictive strength included determination of standardized and fourth-versus-first-quartile odds ratios (ORs), goodness-of-fit measures, and contributing fraction.
RESULTS: The Health Assessment Questionnaire (HAQ) disability index was the strongest clinical predictor of mortality. A 1-SD change in the HAQ resulted in a much larger increase in the odds ratio for mortality compared with a 1-SD change in global disease severity, the next most powerful predictor of mortality (OR 2.31 versus 1.83). Considering the contributing fraction, mortality would be reduced by 50% for the HAQ and by 33% for global disease severity if patients in the fourth quartile for these variables could be switched to the first quartile. Global disease severity, pain, depression, anxiety, and laboratory and radiographic features were significantly weaker predictors. Disease duration, nodules, and tender joint count were clinical variables that provided very little predictive information. In multivariable analyses, HAQ and other patient self-report measures were significantly better predictors than were radiographic and laboratory variables. A single baseline observation provided the least information, with substantially increasing predictive ability associated with 1-year, 2-year, and all-time point followup observations (time-varying covariates).
CONCLUSION: In this large 20-year study from routine clinical practice, the HAQ was the most powerful predictor of mortality, followed by other patient self-report variables. Laboratory, radiographic, and physical examination data were substantially weaker in predicting mortality. We recommend that clinicians collect patient self-report data, since they produce more useful clinical outcome information than other available clinical measures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794820     DOI: 10.1002/art.11024

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  82 in total

1.  [The safety of biologics : a risk-benefit assessment of treating rheumatoid arthritis with biologics based on registry data on mortality].

Authors:  O Sander
Journal:  Z Rheumatol       Date:  2010-11       Impact factor: 1.372

2.  Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients.

Authors:  Kaleb Michaud; Gene Wallenstein; Frederick Wolfe
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-11-15       Impact factor: 4.794

3.  Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials.

Authors:  D Aletaha; M M Ward
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

4.  Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap.

Authors:  Diane Lacaille; J Antonio Avina-Zubieta; Eric C Sayre; Michal Abrahamowicz
Journal:  Ann Rheum Dis       Date:  2016-12-28       Impact factor: 19.103

5.  Predictive value of autoantibody testing for validating self-reported diagnoses of rheumatoid arthritis in the Women's Health Initiative.

Authors:  Brian Walitt; Rachel Mackey; Lewis Kuller; Kevin D Deane; William Robinson; V Michael Holers; Yue-Fang Chang; Larry Moreland
Journal:  Am J Epidemiol       Date:  2013-03-13       Impact factor: 4.897

Review 6.  Co-morbidity index in rheumatoid arthritis: time to think.

Authors:  Yasser El Miedany
Journal:  Clin Rheumatol       Date:  2015-10-26       Impact factor: 2.980

7.  Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.

Authors:  Michael H Schiff; Elaine B Yu; Michael E Weinblatt; Larry W Moreland; Mark C Genovese; Barbara White; Amitabh Singh; Yun Chon; J Michael Woolley
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

8.  The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2010-03-02       Impact factor: 5.156

9.  Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.

Authors:  Kimme L Hyrich; Chris Deighton; Kath D Watson; Deborah P M Symmons; Mark Lunt
Journal:  Rheumatology (Oxford)       Date:  2009-08-25       Impact factor: 7.580

10.  REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis.

Authors:  Peter K Gregersen; Chistopher I Amos; Annette T Lee; Yue Lu; Elaine F Remmers; Daniel L Kastner; Michael F Seldin; Lindsey A Criswell; Robert M Plenge; V Michael Holers; Ted R Mikuls; Tuulikki Sokka; Larry W Moreland; S Louis Bridges; Gang Xie; Ann B Begovich; Katherine A Siminovitch
Journal:  Nat Genet       Date:  2009-06-07       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.